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Abstract 
Background: Colorectal cancer is one of the most common cancers in the 
developed world and is the second leading cause of cancer related mortality 
in the UK and USA. Regular use of aspirin can reduce cancer incidence, 
recurrence, metastasis and cancer related mortality. 
Sources of data: Peer-reviewed journals, governmental and professional 
society publications. 
Areas of agreement: There is a wide body of evidence from observational 
studies and randomized trials that aspirin reduces risk of colorectal cancer. 
There is a delay of several years between initiation and effect. There is 
interpersonal variation in aspirin metabolism but pharmacogenetic testing is 
not yet sufficiently sensitive or specific to justify routine use. 
Areas of disagreement: There is uncertainty about the optimal dose and the 
duration of aspirin. There is debate around use for the general population but 
there is growing consensus on use in those at increased risk of developing 
cancer. 
Growing points: Understanding is growing of the possible mechanisms by 
which aspirin exerts its anti-cancer effects.  Large scale meta-analyses are 
quantifying the cost benefit ratio in the general population.  International trials 
are underway to assess the optimal dose in high-risk individuals and the role 
of aspirin as an adjuvant in those who present with a malignancy.  
Key words: Colorectal cancer, aspirin, and chemoprevention. 
 Does aspirin reduces risk of CRC? 	
 Acetylsalicylic acid is a non-steroidal anti-inflammatory drug (NSAID), 
which is used as an analgesic, anti-pyretic or prophylactic drug for 
cardiovascular diseases. It was first introduced into the market in 1899 by 
Bayer, registered under the name of “Aspirin”. An estimated 10-20 billion 
tablets are consumed annually in the USA alone for cardiovascular diseases 
prophylaxis thus making it one of the most used drugs in the world.1,2 
 
 The first observational evidence favouring aspirin came from a 
Melbourne Case Control study which revealed a 42% reduction in risk of CRC 
in NSAID users.3 This finding was supported by meta-analysis of 18 
subsequent epidemiological studies which revealed a long term risk reduction 
of up to 41% in those randomised to aspirin but with significant variation 
between studies attributed to differing strategies of case selection.4,5  
 
In the 1990’s two large scale randomized controlled trials (RCT) were 
launched involving aspirin as one of their interventions and with cancer as a 
primary endpoint.  The US based Women’s Health Study allocated 39,876 
healthy women to alternate day 100mg aspirin or vitamin E versus controls 
with a ten-year follow up.  At publication in 2005 there was no evidence of a 
reduced cancer risk.6  Following the subsequent publications reported below 
showing a delayed protective effect, the authors returned to the study 
population and discovered an 18% reduction in colorectal cancer among the 
women who had taken the active aspirin (Figure 1A).7 
 
The second RCT had CRC as its primary endpoint; CAPP2 focused on 
people with Lynch syndrome, also known as Hereditary Non-Polyposis Colon 
Cancer, which is caused by loss of function mutation in one of the mismatch 
repair genes.  The first in the series of Cancer Prevention Programme (CAPP) 
trials had focused on adolescents with Familial Adenomatous Polyposis. In 
CAPP1, 206 gene carriers were randomized to 600mg aspirin or placebo and 
30 grams of resistant starch or placebo in a 2x2 factorial design with adenoma 
counts and size of the largest polyp as endpoints.8  Aspirin reduced the size 
of the largest polyp in those who were in study for over a year but was not 
proven to have reduced the number of adenomas, though, their large number 
made analysis difficult.8  Similarly meta-analysis of adenoma prevention trials 
in those with a history of previous colonic neoplasia revealed a modest 
protective effect of regular aspirin use.9  
 
The CAPP2 trial began recruiting in 1998 and extended to 43 centers 
in 16 countries.10 One thousand and nine patients were randomized to either 
600 mg daily aspirin or placebo and 30 grams of a resistant starch, Novelose, 
for 2 to 4 years with a planned follow up to 10 years.  Analysis of adenomas 
and cancers at the end of the intervention stage revealed no significant 
reduction in adenomas and a non-significant excess of major bleeding events 
(7 versus 5) offset by a reduction in probable occlusive events.11 A 
subsequent report analyzed cancers across the cohort when the first recruits 
reached the planned 10-year follow up mark giving a mean follow up of 55.7 
months for the group as a whole. Patients randomized to aspirin had risk 
reduction of up to 60% compared to placebo with a beneficial effect being 
seen for all cancer related to the genetic predisposition such as endometrial 
and upper gastrointestinal cancers (Figure 1B).10 The last of the CAPP2 
recruits began treatment in 2006.  The final analysis covering ten years follow 
up for the whole study population is now in preparation. 
 
The 2011 CAPP2 report coincided with the culmination of major studies 
by Rothwell and colleagues.12 Extended follow-up of over 25,000 people who 
had participated in the early cardiovascular trials showed a significant risk 
reduction in CRC and other cancers commencing around 5 years after the 
initial recruitment compared to the placebo groups.12 Therefore, there is a 
strong evidence for aspirin in reducing CRC risk in both general and high-risk 
populations. 
 
  There is further evidence from observational studies and follow-up 
randomized trials that show reduced risk for distant metastasis in people with 
CRC by up to 70% and reduced risk for distant metastatic CRC by up to 50% 
who take aspirin regularly.13 Allocation to aspirin treatment is also associated 
with reduced risk of death by 50% in people with adenocarcinoma without 
metastasis at initial diagnosis.14 Several RCTs are now underway to validate 
the use of aspirin as an adjuvant, the largest of which is ADD-ASPIRIN 
coordinated by the UK Medical Research Council (www.addaspirintrial.org), 
which will compare daily 100mg and 300mg doses to placebo in a range of 
common cancers such as breast, colorectum, oesophagus and prostate, 
among 10,000 people across centers in the UK and India. 
What dose and duration of aspirin should be prescribed? 	 The CAPP2 trial showed the protective effect of 600mg daily aspirin 
was apparent 5 years after randomization.10 In contrast, the Women’s Health 
Study, showed 18% reduction in gastrointestinal cancers with the effect 
commencing 10 years post randomization in people who were randomized to 
100 mg alternate day aspirin.7 The dose related adverse events in aspirin 
users are well documented so there is a clinical imperative to determine 
whether the difference in these studies is the result of the different doses 
employed or whether people with a hereditary predisposition are more 
responsive to the effects of aspirin.  Support for the latter view comes from the 
recent observational study from the Colon Cancer Family Register.  This very 
large-scale NIH funded observational study contains over 1800 people known 
to have Lynch syndrome.15 Based on their self reported use of NSAID drugs, 
a recent report revealed a major protective effect: 75% risk reduction in those 
on aspirin, with an almost identical effect among those taking ibuprofen.15   
 
In the review of trial participants by Rothwell and colleagues, there was 
evidence of a particular benefit in protection against cancers in the ascending 
colon, an area of particular risk in those with an inherited predisposition.  
While other factors may be at play in those who self report aspirin use, there 
is a plausible argument that the high risk people are more responsive to low 
dose aspirin and may see equivalent reduction in cancer with the lower safer 
doses of aspirin. The CaPP3 trial, which began recruiting in 2014 is a 
randomized trial in patients predisposed to Lynch syndrome where they will 
be randomized to either 100 mg/day, 300 mg/day or 600 mg/day enteric 
coated aspirin for 2 years and compare CRC incidence and bleeding rates 
during the 5-10 year follow-up period (www.capp3.org). 
 
Since aspirin is an anti-platelet agent, bleeding risk is its most 
important side effect. There is a relative increase in risk of haemorrhagic 
strokes by 32-36% and extracranial (mostly gastrointestinal) bleeds by 30-
70% from baseline with low or standard dose aspirin treatment.16 It is possible 
that the approximate 1 in 10,000 extra risk of intracerebral bleeding is in part 
related to unrecognized hypertension; aspirin does not cause such 
hemorrhage.  Rather, it exacerbates the clinical impact of a burst vessel.  In 
the Hypertension Optimal Treatment trial, which examined different 
approaches to the management of high blood pressure, the 18,790 
participants were also randomized to 75 mg/day aspirin or placebo.17  There 
was no difference in the risk of haemorrhagic stroke or fatal complications but 
a clear excess of gastric bleeds in the aspirin group.17  
 
There is a sharp increase in gastrointestinal bleeding risk beyond the 
age of 70 years. Data from the Nurses Health Study shows that the risk of 
gastrointestinal bleeding increases with increase in dose and duration of 
aspirin use.16,18 Hence it is imperative to carry out a study that will measure 
risk-benefit profile of prescribing low dose or high dose aspirin treatment in 
individuals at risk of CRC. There is clear evidence that H. pylori infection 
exacerbates the risk of gastric bleeds in aspirin users.19  All people 
considering long-term aspirin prophylaxis should be investigated for occult 
infection. Therapy is not always effective so a second test after treatment is 
valuable.20 
 
Cuzick and colleagues have examined the overall risk-benefit ratio for 
aspirin. Figure 2 summarizes the overall benefit.  The cardiovascular benefits 
are offset by adverse events in a whole population approach involving 
treatment of 55 to 65 year olds.  When the protective effect against cancer is 
factored in, however, the benefits are clear with an overall 4% reduction in 
mortality.16 
What is the biological mechanism behind aspirin’s chemopreventive 
effect? 
Several biological pathways have been proposed as the source of 
aspirin’s chemopreventive effect. The primary target of aspirin is 
cyclooxygenase-1 (COX1) enzyme where it inhibits its enzymatic activity by 
blocking the access to the catalytic site, which in turn provides anti-platelet 
effect.21 Experimental evidence suggests that cancer patients exhibit 
increased platelet activation, which in turn aids in tumor metastasis by 
protecting cells from immune surveillance and by helping in attaching tumor 
cells to the endothelial lining.22 Thus reduced risk of metastasis observed in 
trials13 could be, at least in part, a direct effect of inhibition of the COX1 
isoform in platelets. 
 
The second isoform of cyclooxygenase, COX2, is induced in response 
to pro-inflammatory and cell division stimuli in monocytes and epithelial cells. 
Its activity has been shown to be modified by aspirin in a dose dependent 
manner23,24 to produce lipoxins that are involved in resolution of inflammatory 
reactions rather than prostaglandin E2 that can cause resistance to apoptosis, 
cell migration and angiogenesis.25,26 Thus modification of the COX2 enzyme 
by aspirin leads to an anti-inflammatory response.  It has been suggested that 
the reduced risk associated with aspirin is mediated through its impact on the 
common  overexpression of COX2 in CRC tumors.27 
 
In addition to the COX-dependent pathway, there is a growing 
evidence of the chemopreventive effects of aspirin through COX-independent 
pathways. To date, the only COX-independent target known to interact with 
aspirin is IκB kinase (IKK). In vivo and in vitro studies have shown that aspirin 
and salicylic acid, a primary metabolite of aspirin, inhibits IKK, which prevents 
activation of NF-κB thereby inhibiting proliferation and reducing inflammatory 
and angiogenic responses.28 However, another study showed activation and 
nuclear translocation of NF-κB in CRC cell lines that was induced by aspirin, 
which was followed by apoptosis.29 The study also showed that this effect was 
specific to the cells of colonic origin only, thus suggesting a tissue specific 
effect of aspirin on NF-κB signaling.29,30  
 
Other chemopreventive mechanisms mentioned in the literature 
includes nuclear caspase dependent cleavage of Sp1, Sp3 and Sp4 
specificity protein transcription factors induced by aspirin,31 decrease in the 
ATPase and selective inhibition of DNA cleavage activity of topoisomerase IIα 
enzyme by salicylic acid,32 inhibition of 6-phosphofructo-1-kinase activity by 
aspirin and salicylic acid,33 and activation of polyamine catabolism by 
increasing expression and activity of spermidine N-acetyltransferase in 
colonic mucosa by aspirin.34 
 
A 3-year interval between colonoscopies has been proven to be 
effective in Lynch syndrome in reducing cancers but the high frequency of 
“interval cancers” prompted most clinical teams to use a 1 to 2 yearly 
interval.35 It seems likely that many Lynch syndrome cancers emerge directly 
from dysplastic mismatch repair deficient crypts rather than having a long 
“adenoma” stage.36  In CAPP2, the reduction in cancer incidence in those 
taking aspirin did not become apparent until around five years after 
commencement.  This suggests that the aspirin is having its primary effect at 
a premalignant stage. The effect of aspirin in the Women’s Health Study 
emerged after a decade and a similar delay is apparent across all studies.  
 
In plants, salicylates are induced in response to infection in order to 
drive apoptosis, or programmed cell death, a form of “scorched earth” 
defense.37  It is plausible that aspirin is having a similar impact on the 
aberrant crypt stem cells that have lost the second allele of the mismatch 
repair gene mutated in the germline.  Such depletion would explain the long 
delay between introduction of aspirin and the fall in cancer rates.38 
Furthermore, the dramatic fall in natural dietary salicylates with modern 
farming methods offers a further explanation of the emergence of CRC as a 
disease of the developed world. 
 
The recent demonstration that the PD-1 blocker, pembrolizumab, can 
destroy MMR deficient cancers by “unleashing” a massive T cell response,39 
taken together with the evidence of a beneficial impact of aspirin on 
premalignant lesions offers the intriguing possibility of a future cancer 
prevention strategy involving routine aspirin prophylaxis, supplemented by 
short episodes of immune “dis-inhibition” in those with a genetic 
predisposition. 
Should aspirin be prescribed as a prophylactic and/or adjuvant therapy? 
    As the case for routine use of prophylactic aspirin grows, so does the 
need to better understand the adverse events and whether it might be 
possible to “personalize” the dose and perhaps avoid use in those most likely 
to suffer an adverse effect. 
 
 Several single nucleotide polymorphisms (SNPs) have been identified 
in genes involved in aspirin metabolism or aspirin’s mode of action that 
modulates its chemopreventive efficacy. For example, SNPs rs1105879 and 
rs2070959 in the UGT1A6 gene, which is involved in aspirin metabolism, have 
been shown to have gene-environment interaction whereby, carriers of the 
SNP variant allele using aspirin had 34% risk reduction in adenoma formation 
compared to individuals with wild type genotype.40 A recent genome wide 
association study based meta-analysis of 10 case-control and cohort studies 
as part of the Genetics and Epidemiology of Colorectal Cancer Consortium 
identified SNP rs2965667 near MGST1 gene which showed a significant 
gene-environment interaction whereby, 34% risk reduction for CRC was 
observed amongst aspirin and/or NSAID users with wild-type genotype but 
89% increase in risk in individuals with the variant allele.41 SNPs in other 
genes such as ODC1, IL16 and COX2 etc. have been identified to modulate 
aspirin’s efficacy.  
 
Despite evidence for genetic variants being one of the sources of 
aspirin’s variable efficacy, the relative effect on the risk of CRC or CRA has 
been modest and hence requires further studies to identify key genetic 
markers, which can be used in clinics to make an informed decision about the 
risk-benefit ratio for an individual. 
 
   A recent analysis of the CAPP2 trial data showed that there was 2.5-
fold increase in risk of developing CRC in overweight or obese patients who 
were genetically predisposed to Lynch syndrome.42 In the sub-group analysis, 
the authors observed that the obesity related excess risk of CRC was 
confined only to the placebo whereas the risk was nullified in the aspirin 
group.42 Hence, the authors suggested prescribing aspirin to overweight and 
obese patients at high risk of developing CRC. Results from the current 
CaPP3 dose inferiority trial would provide answer as to which dose of aspirin 
is likely to provide maximum chemopreventive effect with minimum risk of side 
effects. 
 
Based on their extensive review of the evidence of risk and benefit of 
using aspirin in the general population, Cuzick et al. concluded that 
prophylactic use of 75-325 mg/day aspirin for a minimum of 5 years in the age 
range 55-65 would have a favorable risk-benefit ratio.16 
Conclusion 	 There is overwhelming evidence that aspirin prevents cancer and 
probably also reduces the risk of recurrence when used as an adjuvant. There 
are still many questions around optimal dose and duration and the precise 
mechanism of action but such questions apply to many routine medical 
interventions.  The net benefit in those at increased risk of colorectal cancer is 
now sufficient to justify formal recommendation of aspirin prophylaxis, 
supported by gastric acid suppression if needed and with care to exclude H. 
pylori infection and hypertension to minimize the risk of adverse effects. The 
recent decision by the UK Government to support efforts to facilitate 
repurposing of generic therapies will facilitate an early recognition of aspirin 
as the agent of choice in colorectal cancer prevention. 
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Figure 1: Randomized controlled trial of aspirin versus placebo in (A) 
Women’s Health Study and (B) CAPP2. Graphs depict incidence of 
colorectal cancers in aspirin versus placebo group during the long term follow-
up of the two randomized controlled trials which included cancer as an 
endpoint. Figures reproduced with permission from Cook et al. 2013 and Burn 




Figure 2: Summary estimates of the risk-benefit ratio of long-term 
aspirin use starting at the age of 55 years, on death over the next 20 
years in 100 average risk- men and women. Figure reproduced with 
permission from Cuzick et al. 2014. 
